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Abstract
Modified ultrafiltration is used in cardiac surgery with cardiopulmonary bypass in 
order to diminish systemic inflammatory response syndrome. We aimed to show its 
utility for removing pro-inflammatory agents in operated pediatric patients with con-
genital heart disease and its impact at operative care. A clinical case control trial was 
designed, including patients with simple congenital heart disease operated on with 
cardiopulmonary bypass in a 1-year period. We randomized them to a problematic 
group (with modified ultrafiltration, n = 15) and a control group (without it, n = 16), 
and blood samples to measure interleukins (6 and 10), 3d and 4d complement fraction 
concentrations were taken at the following times: baseline, before cardiopulmonary 
bypass, after it, after modified ultrafiltration, and from the ultrafiltration concentrate. 
Operative clinical end points of success were defined as hemodynamic stability, absence 
of morbidity, and lack of mortality. We observed a higher significant interleukin six 
concentration in the problematic group patients at baseline, as well as a higher removal 
of this pro-inflammatory agent at the ultrafiltration concentrate. Modified ultrafiltration 
has a positive impact over simple congenital heart disease surgery with cardiopulmo-
nary bypass because of removing interleukin 6. We recommend its routinely use when 
hemodynamic conditions are favorable.
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1. Introduction
Cardiopulmonary bypass (CPB) allowed the correction of several congenital heart diseases 
such as intracardiac malformations, but it is well known that this is not a harmless procedure 
because it can lead to a systemic inflammatory response syndrome (SIRS), with activation of 
complement, cytokines, coagulation, and fibrinolysis pathways. Factors that contribute to the 
development of SIRS include blood contact with the synthetic surface of cardiopulmonary 
bypass components, as well as leukocyte and endothelial activation after tissue ischemia and 
reperfusion [1–5]. If there is a severe inflammatory response, it could also develop a multior-
gan dysfunction syndrome that increases morbidity and mortality of the patients at pediatric 
intensive care units (PICUs). Some of the methods used to quantify the magnitude of SRIS 
due to the use of CPB include measurement of blood cytokine concentrations (interleukins 1 
and 6), complement activation products (C3d and C4d), and also coagulation activated factors 
(Von Willebrand, fibrinogen, and factor VIII) [6].
There are several operative strategies for diminishing SRIS and its clinical repercussion, such 
as the use of steroids, modified tubular surfaces for CPB, and ultrafiltration. Despite the single 
or combined use of these strategies [7–12], ultrafiltration is the one that probably removes a 
larger amount of pro-inflammatory agents, as well as water (volume) [13]. The two ultrafil-
tration technique modalities widely accepted for pediatric cardiac surgery are conventional 
ultrafiltration (CUF) and modified ultrafiltration (MUF). CUF is applied in CPB during the 
heart re-warming period and MUF right after ending CPB.
Currently, there is no enough evidence that favor routinely use of MUF [14–19], and we can 
still find some controversies regarding the benefits of this technique [20–22]. Additionally, 
most reports of the literature are focalized in adult cohorts of patients, and there is few infor-
mation provided for pediatric population that shows the real impact of MUF in the remotion 
of pro-inflammatory agents due to CPB use. Therefore, we aimed to study the real utility of 
MUF for remotion of pro-inflammatory agents induced by CPB in operated pediatric patients 
with simple congenital heart disease. We made a special emphasis in hemodynamic variables, 
morbidity and mortality at the operative period.
2. Material and methods
2.1. Study design
A prospective, randomized, analytic, clinical case-control trial was designed at the Department 
of Pediatric Cardiac and Congenital Heart Surgery of a single center during a 1-year period of 
time. Inclusion criteria were: age ≤ 18 years and simple congenital heart disease that required 
elective surgical treatment with CPB use for at least 30 minutes. Exclusion criteria were pre-
operative renal failure, preoperative cardiogenic shock requiring the use of inotropes, preop-
erative sepsis, preoperative mechanical ventilatory support ≤48 hours, preoperative lactate 
concentration ≥ 3 mmol/L, and cardiac reoperation. Patients were randomized in two study 
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groups: problematic group (with MUF) and control group (without MUF). With the use of an 
electronic URNA software, a statistical person randomized the patients and told the perfusion-
ist who was the only surgical team person informed about the results of randomization. All 
patients included in this study were operated on with informed consent signed by their par-
ents or tutors. The study was also approved by our institutional research and ethics committee.
2.2. Modified ultrafiltration (MUF) technique
Patients randomized to problematic group (with MUF), when informed to the perfusionist, 
were prepared for CPB with an additional MUF set. Once CPB was ended and hemodynamic 
stability of the patient was provided, the surgeon was told not to remove the venous can-
nula, and the venous line was clamped just before its connection to the reservoir. Arterial 
and venous line pathways were released in order to begin MUF with a 10–20 ml/kg/min flow. 
MUF continuous flow was achieved pumping the venous residual reservoir volume by means 
of the arterial line to the patient. A 150–200 mmHg venous vacuum was applied when needed. 
MUF lasted 10–20 minutes in order to reach a desired hematocrit level and obtain a suitable 
volume and electrolyte balance. MUF was stopped in case of hemodynamic instability. Once 
ended, MUF volume was restored to the patient from the hemofilter and venous cannula, 
allowing the surgeon for decannulation of the patient.
2.3. Biochemical and clinical operative analysis
Biochemical and clinical results were compared between the two study groups at the opera-
tive period. Biochemical results were the concentration of cytokine (interleukin 6 and 10) and 
complement activated products (C3d and C4d). These concentrations were measured from 
blood samples at the following times: T0 (baseline, at the beginning of anesthesia induction), 
T1 (before CPB), T2 (immediately after CPB), and T3 (immediately after MUF, in the problem 
group). The same agents were measured in the MUF fluid concentrate of the problematic group 
after the procedure (T4). Clinical operative results were evaluated in terms of hemodynamic 
instability (>20% post-CPB variation respect to previous CPB values of at least three of the 
following five hemodynamic variables: heart rate, systolic, diastolic and mean blood pressure, 
and central venous pressure), operative morbidity, and mortality. Operative clinical end points 
of success were defined as hemodynamic stability, absence of morbidity, and lack of mortality.
2.4. Laboratory analysis of the fluid samples
All patient samples were obtained from central or peripheral blood and collected in tubes 
without heparin (vacutainer, Becton Dickinson). A 3-ml blood sample was obtained for each 
of the study times (T0, T1, T2, and T3). The same volume of T4 samples were obtained from 
the ultrafiltration fluid concentrate. All of the samples were centrifugated at 3000 rpm during 
15 minutes, 4°C, and cryopreserved in aliquots of 1.5 ml at −75°C. Interleukin concentra-
tions (IL-6 and IL-10) were measured by means of an ELISA sandwich technique with the use 
of monoclonal antibodies (PeproTech, New Jersey, EUA). Complement activation products 
(C3d and C4d) were measured with the same technique, using commercial kits (Bachem, San 
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Carlos, CA, EUA). Optical density was determined at 450 nm in the ELISA plate detector. 
Concentrations of IL-6, IL-10 (pg/ml) as well as C3d and C4d (ng/ml) were calculated by 
means of a GraphPad Software v. 4.2.
2.5. Statistical analysis
Information was registered in evaluation sheets, stored in an electronic Excel page, and 
analyzed by means of a Prisma Graphics v 3.1 statistical software. Continuous variables are 
presented as a mean, standard deviation, and variability ranges (minimum and maximum). 
Categorical data are presented by means of frequency and percentages in relation to the popu-
lation at risk. Comparison between the two study groups was made by means of a Student t test 
for continuous variables. A chi-square (χ2) test was used for comparing categorical variables 
with a 95% confidence interval (CI). A p value < 0.05 was considered as statistically significant.
3. Results
A total of 31 patients were enrolled and randomized to this trial: 15 to the problematic group 
(with MUF) and 16 to the control group (without MUF).
3.1. Preoperative characteristics
Table 1 shows the type of congenital disease that was operated by means of CPB in both 
groups of study. There are no differences in the total number of congenital heart disease in 
the studied groups, but control group (without MUF) showed more patients with AV channel 
than the problematic group (with MUF).
Congenital heart disease type Total series 
(n = 31)
n (%)
Problematic group  
(With MUF)  
(n = 15)
n (%)
Control group 
(Without MUF) 
(n = 16)
n (%)
P  
OR (95% CI)
Ventricular septal defect 13 (42%) 8 (52%) 5 (31%) NS
Balanced AV channel 8 (26%) 1 (7%) 7 (44%) 0.0373 0.09 
(0.0096 – 0.8770)
Congenital mitral valve disease 4 (13%) 3 (20%) 1 (6%) NS
Sub aortic membrane 3 (10%) 1 (7%) 2 (13%) NS
Right ventricular outflow tract 
obstruction
1 (3%) 1 (7%) 0 (0%) NS
Double chamber right ventricle 1 (3%) 1 (7%) 0 (0%) NS
Atrial septal defect 1 (3%) 0 (0%) 1 (6%) NS
TOTAL 31 (100%) 15 (100%) 16 (100%) NS
Table 1. Congenital heart disease type in the studied groups.
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Variable Total series
n (%) or mean ± SD 
(range)
Problematic group 
(with MUF)
n (%) or mean ± SD 
(range)
Control group 
(without MUF)
n (%) or mean ± SD 
(range)
p
Age (years) 4.26 ± 4.11 (0.38–17.18) 37 ± 14 (18–76) 31 ± 11 (18–56) NS
Gender
Male 12 (39%) 8 (53%) 4 (25%) NS
Female 19 (61%) 7 (47%) 12 (75%) NS
Anthropometric data
Weight (kg) 14.9 ± 10.8 (4–47) 14.1 ± 10.4 (4–38.3) 15.9 ± 11.6 (5.3–47) NS
Height (cm) 90 ± 31.1 (12–159) 94.2 ± 31.2 (55–158) 86 ± 31.5 (12–159) NS
Body surface area (m2) 0.56 ± 0.27 (0.25–1.32) 0.58 ± 0.31 (0.25–1.32) 0.53 ± 0.18 (0.28–0.78) NS
Circulating blood volume (ml) 1032 ± 627 (343–2660) 1164 ± 756 (343–2660) 867 ± 385 (452–1560) NS
Cardiovascular background
Previous surgery 0 (0%) 0 (0%) 0 (0%) NS
Previous catheterization 2 (6%) 0 (0%) 2 (6%) NS
Pathologic background
Pre-operative infection 1 (3%) 0 (0%) 1 (6%) NS
Pulmonary artery hypertension 4 (13%) 0 (0%) 4 (25%) NS
None 26 (84%) 15 (100%) 11 (69%) NS
Syndromes
Down’s syndrome 3 (10%) 0 (0%) 3 (19%) NS
None 28 (90%) 15 (100%) 13 (81%) NS
NYHA/Ross pre-operative functional class
I 8 (26%) 4 (27%) 4 (25%) NS
II 21 (68%) 9 (60%) 12 (75%) NS
III 2 (6%) 2 (13%) 0 (0%) NS
Operative risk
RACHS-1 score 2.4 ± 0.5 (1–3) 2.4 ± 0.5 (2–3) 2.4 ± 0.6 (1–3) NS
Basic Aristoteles 7.2 ± 1.5 (3–9) 7 ± 1.2 (6–9) 7.4 ± 1.9 (3–9) NS
Complete Aristoteles 8.1 ± 1.8 (4–11) 7.8 ± 1.5 (6–10) 8.4 ± 2.1 (4–11) NS
Preoperative morbidity
Mechanic ventilation 0 (0%) 0 (0%) 0 (0%) NS
Pre-operative inotropic support 0 (0%) 0 (0%) 0 (0%) NS
Pre-operative infection 1 (3%) 0 (0%) 1(6%) NS
None 30 (97%) 15 (100%) 15 (94%) NS
Pre-operative laboratory exams
Lactate 1.2 ± 0.3 (0.6–1.7) 1.2 ± 0.3 (0.7–1.7) 1.1 ± 0.3 (0.6–1.5) NS
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Table 2 shows the rest of preoperative characteristics in both studied groups. Note that there 
are no statistical differences in all variables analyzed between the two groups.
Although more random patients with AV channel in the control group, the rest of the preop-
erative data showed that both groups are absolutely comparable.
3.2. Biochemical operative results
Table 3 compares the concentration of pro-inflammatory agents between groups before surgi-
cal correction (T0). Note a baseline elevated concentration of IL-6 in the problematic group 
(with MUF), without differences in both groups for the rest of pro-inflammatory agents (IL-10, 
C3d, and C4d).
On the other hand, Table 4 shows a lack of statistical significant difference in the concentra-
tions of pro-inflammatory agents at the control group before surgical correction (T0) and after 
CPB (T2).
Finally, Table 5 shows the comparison between concentration of pro-inflammatory agents 
in the problematic group before surgical correction (T0) and after MUF (T4). There is a sta-
tistically significant removal of IL-6, but no difference in the concentrations of the rest pro-
inflammatory agents analyzed (IL-10, C3d, and C4d).
Variable Total series
n (%) or mean ± SD 
(range)
Problematic group 
(with MUF)
n (%) or mean ± SD 
(range)
Control group 
(without MUF)
n (%) or mean ± SD 
(range)
p
Creatinine 0.4 ± 0.1 (0.2–0.7) 0.4 ± 0.1 (0.2–0.7) 0.4 ± 0.1 (0.3–0.5) NS
Perfusion variables
Oxygenator type
Baby Rx 14 (52%) 7 (47%) 7 (58%) NS
Terumo SX10 6 (22%) 4 (27%) 2 (17%) NS
Terumo SX18 1 (4%) 1 (7%) 0 (0%) NS
Mini max 5 (19%) 2 (13%) 3 (25%) NS
Safe Mini 1 (4%) 1 (7%) 0 (0%) NS
Arterial filter use 18 (67%) 12 (80%) 6 (50%) NS
Surgical variables
CPB time (min) 81.9 ± 26.9 (40–131) 76.5 ± 23.7 (40–122) 87 ± 29.4 (41–131) NS
Aortic cross clamp time (min) 53.7 ± 23.6 (12–96) 49.5 ± 21.8 (18–90) 57.6 ± 25.2 (12–96) NS
Temperature (°C) 27 ± 1.6 (24–30) 27 ± 1.5 (24–29) 27.3 ± 1.8 (24–30) NS
Anterograde cardioplegia 29 (94%) 14 (93%) 15 (94%) NS
Blood cardioplegia 29 (94%) 14 (93%) 15 (94%) NS
Table 2. Pre-operative characteristics of the studied groups.
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3.3. Clinical operative results
Table 6 summarizes the comparison of clinical end point variables in both groups of study 
(with and without MUF). There is a statistically significant decrease of hemoglobin (Hb) in 
the problematic group after MUF compared with the baseline level, which is not observed in 
the control group.
Both groups show an increase in lactate levels and heart rate after surgery when compar-
ing these values with the baseline ones before CPB. Control group (without MUF) showed a 
Pro-inflammatory agent T0 problematic group (with MUF)
n = 15
Mean ± DE
T0 control group (without MUF)
n = 16
Mean ± DE
p
C3d (ng/ml) 368.66 ± 331.87 413.248 ± 316.804 NS
C4d (ng/ml) 199.57 ± 201.56 213.89 ± 116.72 NS
IL-6 (pg/ml) 672.249 ± 433.186 246.874 ± 365.69 0.0061
IL-10 (pg/ml) 239.698 ± 381.517 299.618 ± 370.148 NS
Table 3. Comparison between concentrations of pro-inflammatory agents in both groups of study (with and without 
MUF) at baseline (T0).
Pro-inflammatory agent T0 control group (without MUF)
n = 16
Mean ± SD
T2 control group (without MUF)
n = 16
Mean ± SD
p
C3d (ng/ml) 413.248 ± 316.804 264.33 ± 198.12 NS
C4d (ng/ml) 213.89 ± 116.72 210.65 ± 141.13 NS
IL-6 (pg/ml) 246.874 ± 365.69 289.499 ± 301.913 NS
IL-10 (pg/ml) 299.618 ± 370.148 387.26 ± 306.07 NS
Table 4. Comparison between concentrations of pro-inflammatory agents at T0 (baseline) and T2 (after CPB) for the 
control group (without MUF).
Pro-inflammatory 
agent
T0 problematic group (with MUF) 
n = 15
Mean ± SD
T4 problematic group (without MUF) 
n = 15
Mean ± SD
p
C3d (ng/ml) 368.66 ± 331.87 379.99 ± 264.64 NS
C4d (ng/ml) 199.57 ± 201.56 172.89 ± 139.64 NS
IL-6 (pg/ml) 672.249 ± 433.186 366.31 ± 280.25 0.0293
IL-10 (pg/ml) 239.698 ± 381.517 230.453 ± 352.27 NS
Table 5. Comparison between concentrations of pro-inflammatory agents at baseline (T0) and after MUF (T4) for the 
problematic group (with MUF).
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Problematic group (with MUF) Control group (without MUF) Problem vs control groups (with vs 
without MUF)
Operative clinical end point variable Control 
group
Problematic 
group
p Control 
group
Problematic 
group
p Problematic group Control 
group
P
Before CPB After MUF Before CPB After MUF After MUF After CPB
n/total n 
(%) or
n/total n (%) or n/total n 
(%) or
n/total n (%) or n/total n (%) or n/total n 
(%) or
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Laboratory exams
Hematocrit (%) 38 ± 7 34 ± 6 NS 37 ± 5 34 ± 7 NS 34 ± 6 34 ± 7 NS
Hemoglobin (g/dl) 14 ± 5 11 ± 2 0.0344 12 ± 2 11 ± 2 NS 11 ± 2 11 ± 2 NS
CPB hematocrit (%) 26 ± 5* 24 ± 4* NS
Lactate (mmol/L) 1.2 ± 0.3 3.5 ± 1.4 0.0001 1.1 ± 0.3 3.3 ± 1.2 0.0001 3.5 ± 1.4 3.3 ± 1.2 NS
Hemodynamic variables
Heart rate (beats per 
minute)
97 ± 15 113 ± 18 0.012 97 ± 16 112 ± 15 0.0116 113 ± 18 112 ± 15 NS
Systolic blood pressure 
(mmHg)
85 ± 16 89 ± 12 NS 83 ± 10 90 ± 20 NS 89 ± 12 90 ± 20 NS
Diastolic blood pressure 
(mmHg)
53 ± 15 52 ± 12 NS 49 ± 7 49 ± 12 NS 52 ± 12 49 ± 12 NS
Mean blood pressure 
(mmHg)
64 ± 18 61 ± 12 NS 64 ± 13 64 ± 17 NS 61 ± 12 64 ± 17 NS
Central venous pressure 
(mmHg)
10 ± 8 12 ± 7 NS 8 ± 1 10 ± 3 0.0203 12 ± 7 10 ± 3 NS
Operative morbidity and mortality
Morbidity 3 
(20%)
1 (6%) NS
Mortality 0 (0%) 0 (0%) NS
*CPB measured values (due to hemodilution).
Table 6. Comparison between operative clinical end point variables in both groups of study (with and without MUF).
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statistically significant increase in central venous pressure after CPB compared with the ones 
before CPB. There were no differences before and after CPB in the other hemodynamic vari-
ables (systolic, diastolic, and mean blood pressures), nor inoperative morbidity and mortality. 
Successful clinical operative endpoints were archived in both groups of study.
4. Discussion
Cardiopulmonary bypass (CPB) is able to trigger a systemic inflammatory response syn-
drome (SRIS) due to several factors that include: (1) cell activation secondary to contact with 
CPB synthetic surfaces, (2) mechanic stress, (3) tissue ischemia and reperfusion, (4) hypoten-
sion, (5) non-pulsatile flow, (6) hemodilution relative anemia, (7) blood and blood products 
transfusion, (8) heparin and protamine administration, and (9) hypothermic effects. CPB acti-
vates the vessels endothelium and releases pro-inflammatory agents such as tumoral necrosis 
factor α (TNF-α), interleukins, and endotoxins. These agents also activate the intracellular 
transcription factor that increases endothelial pro-inflammatory cytokines and the molecular 
expression of leukocyte adhesion.
It is well known the fact that younger age increases even more the inflammatory effects of 
CPB. Some reasons include increased metabolic demand in these patients, hyperactivity of 
their pulmonary vessels, immaturity of their organs/systems, and altered homeostasis. The 
risk is particularly high in neonates and young infants due to mismatch between CPB and 
patient’s size, with CPB circuit volume usually 200–300% higher than that of the patient. 
Additionally, an increased metabolic demand requires elevated pump flow up to 200 ml/
kg−1/min−1 in neonates. Combining a relative major size of CPB with an increased perfusion 
rate leads to a greater blood exposure to synthetic surfaces of the circuit components [23]. 
In our series, there was no age difference between the studied groups, and it is important to 
highlight that none of the groups included neonate patients for the reasons already discussed.
One of the most involved cytokines in SRIS development is, indeed, IL-6. Increased con-
centrations of IL-6 have been reported in patients with postoperative complications, and a 
correlation with posterior left ventricular wall dyskinesia detected by means of transesopha-
geal echocardiography has been established. IL-6 is also an endogenous pyrogen agent that 
activates acute phase reactant proteins. Concentration of IL-6 increases independently of the 
oxygenator type, degree of hypothermia, or heparin use in the CPB circuit surfaces [24, 25]. 
Although in our study IL-6 concentrations were significantly higher before surgery in the 
problematic group than in the control group, this agent is also the one that is significantly 
more removed by MUF. This is probably the most relevant fact of our study because it shows 
that the benefit of MUF in congenital heart disease surgery is the removal of IL-6, an impor-
tant pro-inflammatory agent, particularly in patients that SRIS is enhanced because of the 
immaturity of their immune system. Another effect that is important to discuss is the fact 
that, if MUF benefits patients with simple congenital heart disease surgery as were the ones 
included in our study, it would indeed improve operative outcomes in those operated on for 
complex congenital heart disease [26]. This single fact justifies the routine use of MUF in all 
patients with congenital heart disease that is operated on with CPB.
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There are several additional methods, despite ultrafiltration, that had been developed in order 
to diminish SRIS secondary to CPB at surgical correction of congenital heart disease in pediatric 
population. Some of them are steroids (e.g., dexamethasone 10–30 mg/kg 6–12 hours before 
CPB) and modified tubular synthetic surfaces in the CPB circuit. However, none of these meth-
ods is as such as useful for this purpose as MUF, which is established right after ending the 
CPB and before decannulation of the patient [27]. Since 1973, different types of hemofilters 
have been developed in order to remove priming volume (water) following the principle of 
pressure gradient, particularly those made of polycarbonate. These filters have been replaced 
by the ones made out of polysulfonate in 1986 and later by the current generation of polyamide 
hemofilters. These are the most practical ones because of its greater biocompatibility, reduced 
surface, and more ultrafiltration effectiveness due to a less than physiological pressure.
The effectiveness of ultrafiltration for removing pro-inflammatory agents depends also on the 
type of hemofilter and on the modality of ultrafiltration procedure used. Kosik et al comments 
Berdat´s study on the effectiveness of polysulfonate filters vs polyamide ones in the two ultrafil-
tration modalities for the removal of pro-inflammatory agents such as IL-6, IL-10, and TNFα [3]. 
They prove that IL-6 was better removed by conventional ultrafiltration (CUF) with poliari-
letersulfonate filter, while TNFα was better removed by modified ultrafiltration (MUF) and 
poliariletersulfonate filter. The rest of the pro-inflammatory agents was not modified neither for 
the ultrafiltration modality nor for the hemofilter type. Therefore, it seems that MUF with poli-
ariletersulfonate hemofilter is the better strategy for removing pro-inflammatory agents in pedi-
atric patients with congenital heart surgery. Our results are based on the ultrafiltration modality 
rather than the type of filter, since the material of hemofilters that we used was variable.
It has been reported that MUF is not only useful for removing extracellular fluid excess, but 
also cytokines and other inflammatory agents triggered by CPB and surgical trauma. There is 
some controversy in the literature regarding the efficacy of filters in the removal of cytokines, 
as well as in the differences between the two ultrafiltration modalities [28]. Additionally, the 
comparative results between both ultrafiltration modalities are difficult to interpret due to 
variations in the ultrafiltration technique, equipment, definitions and objectives, and mea-
surements of cytokines. Finally, it is still not known if the clinical benefits of MUF are due to 
the removal of cytokines and other inflammatory agents, or to the isolated reduction of tissue 
edema [29–33].
5. Conclusion
Based on the results of this study [34], we can say that although the baseline concentrations 
of IL-6 in the patients of the problematic group were higher in relation to those of the control 
group, the removal of this pro-inflammatory agent by MUF was statistically significant. This 
indicates that MUF is a procedure that can benefit pediatric patients with congenital heart 
disease undergoing CPB because it is able to decrease the concentration of IL-6. Therefore, we 
consider that the use of MUF in pediatric patients should be routinely recommended as long 
as hemodynamic conditions allow it.
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